Zeo Scientifix Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Zeo Scientifix Inc 's ROA in the second quarter of 2026?
Zeo Scientifix Inc recorded a cumulative net loss of $-4 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -180.76%.

However, within the Healthcare sector 840 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Apr 30 2026 quarter, so far to 4459, from total ROA ranking in the first quarter of 2026 at 5291.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Apr 30 2026) II. Quarter	(Jan 31 2026) I. Quarter	(Oct 31 2025) IV. Quarter	(Jul 31 2025) III. Quarter	(Apr 30 2025) II. Quarter
Y / Y Total Assets Change	170.8 %	-1.29 %	-7.06 %	-25.62 %	-25.72 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-4	-5	-6	-6	-5
Return On Assets (TTM)	-180.76 %	-333.98 %	-358.27 %	-379.62 %	-286.17 %
BPSR's Total Ranking	# 4459	# 5291	# 4707	# 4787	# 4816
Total Assets (TTM) in million	4	2	2	2	1
Seq. Total Assets Change	153.99 %	0.2 %	-7.57 %	15.12 %	-7.42 %
Seq. Net Income Change	-	-	-	-	-

BPSR's 5 Years Annual ROA >> Back to BPSR Management Effectiveness >> Compare BPSR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 130
Sector	# 841
Overall	# 4413

Return On Assets Statistics
High	Average	Low
41037.74 %	1777.36 %	-10069.21 %
(Jul 31 2014)		(Jan 31 2017)

Financial Statements
Zeo Scientifix Inc 's Assets	$ 4 million	BPSR's Balance sheet
Zeo Scientifix Inc 's Income	$ 0 million	Quarterly BPSR's Income Statement
BPSR's Income by Division		See BPSR's Income by Division

Annual Return On Assets	(Oct 31 2025) FY 2024	(Oct 31 2023) FY 2023	(Oct 31 2022) FY 2022	(Oct 31 2021) FY 2021	(Oct 31 2020) FY 2020
Y / Y Total Assets Change	-45.01 %	-55.13 %	220.79 %	57.3 %	96.2 %
Total Assets in million	2	3	6	2	1
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-6	-7	-9	-13	-13
Annual Return On Assets	-360.85 %	-251.12 %	-143.48 %	-659.96 %	-1023.99 %

BPSR's 5 Years Annual ROA >> Back to BPSR Management Effectiveness >> Compare BPSR ROA to its Competitors

More Return On Assets Ratios
BPSR's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BPSR's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BPSR's Competitors
Subscribers only: Roa for Zeo Scientifix Inc 's Suppliers
Subscribers only: Return On Assets for BPSR's Customers

You may also want to know
BPSR's Roi	BPSR's Inventory Turnover Ratio	BPSR's Growth Rates	BPSR's Dividend Comparisons
	BPSR's Profitability Ratios	BPSR's Asset Turnover Ratio	BPSR's Dividend Growth
BPSR's Roe	BPSR's Valuation Ratios	BPSR's Financial Strength Ratios	BPSR's Dividend Payout Ratio

Companies with similar Return On Assets at Apr 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-17T09:33:11+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.